key: cord-0734803-y0gvhasu authors: Stegmann, Kim M.; Dickmanns, Antje; Gerber, Sabrina; Nikolova, Vella; Klemke, Luisa; Manzini, Valentina; Schlösser, Denise; Bierwirth, Cathrin; Freund, Julia; Sitte, Maren; Lugert, Raimond; Salinas, Gabriela; Meister, Toni Luise; Pfaender, Stephanie; Görlich, Dirk; Wollnik, Bernd; Groß, Uwe; Dobbelstein, Matthias title: The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models date: 2021-06-06 journal: Virus Res DOI: 10.1016/j.virusres.2021.198469 sha: 69301888a9193d457393ee31c30717bff0d27ed3 doc_id: 734803 cord_uid: y0gvhasu The search for successful therapies of infections with the coronavirus SARS-CoV-2 is ongoing. We tested inhibition of host cell nucleotide synthesis as a promising strategy to decrease the replication of SARS-CoV-2-RNA, thus diminishing the formation of virus progeny. Methotrexate (MTX) is an established drug for cancer therapy and to induce immunosuppression. The drug inhibits dihydrofolate reductase and other enzymes required for the synthesis of nucleotides. Strikingly, the replication of SARS-CoV-2 was inhibited by MTX in therapeutic concentrations around 1 µM, leading to more than 1000-fold reductions in virus progeny in Vero C1008 (Vero E6) and ∼100-fold reductions in Calu-3 cells. Virus replication was more sensitive to equivalent concentrations of MTX than of the established antiviral agent remdesivir. MTX strongly diminished the synthesis of viral structural proteins and the amount of released virus RNA. Virus replication and protein synthesis were rescued by folinic acid (leucovorin) and also by inosine, indicating that purine depletion is the principal mechanism that allows MTX to reduce virus RNA synthesis. The combination of MTX with remdesivir led to synergistic impairment of virus replication, even at 100 nM MTX. The use of MTX in treating SARS-CoV-2 infections still awaits further evaluation regarding toxicity and efficacy in infected organisms, rather than cultured cells. Within the frame of these caveats, however, our results raise the perspective of a two-fold benefit from repurposing MTX for treating COVID-19. Firstly, its previously known ability to reduce aberrant inflammatory responses might dampen respiratory distress. In addition, its direct antiviral activity described here would limit the dissemination of the virus. limiting both the pathogenesis of pneumonia and also the spread of virus within a patient. The SARS-CoV-2 pandemic has so far infected > 160 million people, with > 3.4 million deaths ascribed to COVID-19 so far (May 2021). The fast spread of the virus raises the need for readily available therapies, preferably through drug repurposing. In addition to viral proteins, cellular pathways represent attractive targets, with fewer opportunities for viruses to develop drug resistance. The life cycle of SARS-CoV-2 comprises the replication of the viral RNA genome, one of the longest single strand RNA genomes among all viruses. Large amounts of RNA need to be synthesized, often subgenomic for translation at ribosomes, as well as full-length RNA genomes for incorporation into virus progeny. Thus, high amounts of ribonucleotides are required in infected cells for virus replication. This makes nucleotide biosynthesis an attractive target for drugs to interfere with the propagation of the virus in infected individuals. One way of suppressing nucleotide biosynthesis consists in the use of folate antagonists. This class of drugs, upon cellular uptake, diminishes the regeneration of tetrahydrofolate (THF) from dihydrofolate (DHF), and the subsequent transfer of methyl groups required for the synthesis of purine nucleotides, as well as desoxythymidine monophosphate and S-adenosyl methionine. Especially the lack of purine nucleotides can be expected to diminish the synthesis of virus RNA. Folate antagonists have not been broadly evaluated as antivirals, with the exception of some flaviviruses (1, 2) . In contrast, sulfonamides and trimethoprim are routinely used for treating bacterial infections, and their mechanism of action is to prevent the synthesis of folic acid in bacteria (3) . Methotrexate (MTX), along with the closely related aminopterin, represents the most established antifolate to act on eukaryotic cells. They belong to the earliest cancer drugs whatsoever, since they were first characterized by Sidney Farber and colleagues in the forties of the last century (4) , and have been in clinical use ever since. They were first applied at high doses to treat leukemia as well as solid malignancies. Later, however, they were found to suppress the inflammatory and immune response even at low doses (5) . Until today, MTX is broadly used to treat rheumatoid arthritis and other autoimmune diseases, and it is also part of current standard anti-cancer regimens. It is bioavailable orally and parenterally, inexpensive, and, with seven decades of clinical use, one of the best-characterized drugs in the clinics. Its disadvantages are often a result of long-term treatment, which would not be necessary in the case of treating an acute virus infection. Of note, however, pregnancy is a contraindication for MTX, due to its negative impact on fastproliferating embryonal cells (6) . Moreover, high doses of MTX can cause severe mucositis (7) . Thus, therapies with MTX do require close monitoring by trained personnel. Here we show that MTX reduces SARS-CoV-2 replication up to 1000-fold, at concentrations that are clinically achievable, in Vero cells as well as Calu-3 cells that resemble bronchial epithelial cells. This effect of MTX can be largely ascribed to impaired purine synthesis. Furthermore, MTX synergizes with the antiviral purine analogue remdesivir to diminish virus replication. Thus, MTX might not only reduce inflammation in the context of COVID-19 but also display a direct antiviral activity. Vero E6 cells (Vero C1008) were kindly provided by C. Stahl-Hennig, German Primate Center Göttingen, Germany. Cells were maintained in Dulbecco"s modified Eagle"s medium (DMEM with GlutaMAX TM , Gibco) supplemented with 10% fetal bovine serum (Merck), 50 units/ml penicillin, 50 μg/ml streptomycin (Gibco), 2 µg/ml tetracycline (Sigma) and 10 µg/ml ciprofloxacin (Bayer) at 37°C in a humidified atmosphere with 5% CO 2 . The human lung epithelial cell line Calu-3 was purchased from ATCC (HTB-55) and maintained in Eagle"s Minimum Essential Medium (EMEM, ATCC) supplemented with 10% fetal bovine serum and penicillin/streptomycin. Cells were routinely tested and ensured to be negative for mycoplasma contamination. SARS-CoV-2 was isolated from a patient sample taken in March 2020 at Göttingen, Germany. Throat swab material was mixed with medium containing 2% fetal bovine serum and used to inoculate Vero E6 cells for five days. The supernatant was passaged twice more to expand the virus. This cell culture supernatant was titrated for virus quantification by immunofluorescence analysis to contain 300,000 fluorescent focus units (FFU)/mL according to established protocols (8, 9) and by qRT-PCR ( Figure 1B) , and this was used as our virus stock in all experiments. 30,000 cells per well were seeded into 24-well-plates using medium containing 2% fetal bovine serum and incubated for 8 hours at 37 °C. Cells were treated with methotrexate (Selleckchem S1210), remdesivir (Selleckchem S8932), palbociclib (Sigma-Aldrich PZ0199), leucovorin (Selleckchem S1236) and inosine (Selleckchem S2442) at the concentrations indicated in the figure legends. When preparing stock solutions, methotrexate and remdesivir were dissolved in DMSO; palbociclib, leucovorin and inosine in water. After 24 hours, the cells were infected with virus stocks corresponding to 1*10 7 RNA-copies of SARS-CoV-2 (= 30 FFU, corresponding to the high particle-to-PFU ratio observed for SARS-CoV-2 previously (10)) and incubated for 48 hours at 37 °C. To determine the Median Tissue Culture Infectious Dose (TCID 50 Vero E6 cells were seeded into 24-well-plates and treated/infected as indicated. After fixation of the cells and DAPI staining to visualize nuclear DNA, the numbers of nuclei were counted automatically using the Celígo ® S Imaging Cytometer (Nexcelom Bioscience). 3,500 Vero E6 cells were seeded onto 96-well-plates and treated with MTX and/or remdesivir as indicated for 72 hours. Lactate dehydrogenase (LDH) is a cytosolic enzyme that is released into the cell culture supernatant upon disruption of the plasma membrane and was used to determine cytotoxicity. The LDH release into the cell culture medium was measured and quantified by bioluminescence using the LDH-Glo TM Cytotoxicity Assay kit (Promega). 2 µL of 10% Triton X-100 were added to untreated cells for 10 minutes to determine the maximum LDH release. Percent cytotoxicity reflects the proportion of LDH released to the media (compared to the overall amount of LDH in the cells) and was calculated using the following formula: For cell cycle analysis, cells were harvested in cold storage buffer (1% FBS in PBS) after treatment/infection, fixed in ethanol, and stained with propidium iodide (Sigma-Aldrich). Cell cycle profiles were generated using a Guava EasyCyte Plus system (Millipore) and analyzed by using the Cyto Soft 5.3 software. Quality and integrity of RNA were assessed using the Fragment Analyzer (Advanced the --very-sensitive end-to-end setting. Resulting SAM files were processed using SAMTOOLS/1.9 (14) . In short, SAM files were converted into BAM files using samtools view, followed by merging of technical replicates using samtools merge. The resulting BAM files were subsequently re-sorted according to genomic coordinates using samtools sort, PCR duplicates were removed using samtools markdup with default settings, and the corresponding index files were generated using samtools index. Sequencing depth was determined using samtools depth and the average read coverage per base was calculated taking the average sequencing depth for all positions across the reference genome. Genomic tracks of mapped reads were calculated using the bamCoverage function of DEEPTOOLS/3.0.1 (15) with the following settings: -e 100, --ignoreDuplicate, --smoothLength 60, --binSize 20, --samFlagInclude 64. SNPs present in the isolated virus were identified using bcftools mpileup with default settings, followed by bcftools call with -mv and -Ob settings of BCFTOOLS/1.9 (Samtools). Identified variants were filtered and converted into VCF files using bcftools view with the -i "%QUA >=150" setting. Genomic tracks as well as VCF files were visualized using the Integrative Genomics Viewer v2.3 (16) (17) (18) . Statistical testing was performed using Graph Pad Prism 6 (RRID:SCR_002798). A two-sided unpaired Student"s t-test was calculated. Significance was assumed where p-values ≤ 0.05. Asteris s represent significance in the following way: ****, p ≤ 0.0001, ***, p ≤ 0.005; **, p ≤ 0.01; *, p ≤ 0.05. Infection with SARS-CoV-2 produces >10 6 copies of genomic virus RNA per cell. We isolated SARS-CoV-2 from a patient sample taken in March 2020 at Göttingen, Germany. Throat swab material was used to inoculate Vero C1008 cells (i.e. Vero E6 cells; shortly termed Vero cells from here on). The supernatant was passaged twice more to expand the virus, and cell supernatant was subjected to deep sequencing analysis. More than 80*10 6 reads, 2*150bp each, were taken and aligned with the published genome sequence of the first Wuhan strain of SARS-CoV-2 (12) . >97% of all reads corresponded to the virus. Comparing the Göttingen and Wuhan strains, only 8 nucleotide deviations were found (Fig. 1A) . Most of these deviations were from C to U, arguing that they might have occurred through RNA deamination rather than misincorporation by the polymerase. Among the deviations was a nucleotide exchange leading to the mutation D614G in the Spike (S) protein that was recently reported to increase the number of S proteins displayed on the viral envelope (19, 20) . Of note, however, no change in the coding region for the furin cleavage site of the S protein (21-23) was observed. Next, we detected and quantified the viral RNA released from infected cells. With decreasing virus inoculate, the yield of virus progeny after two days first remained at a maximum and then steeply decreased (Fig. 1B) . The decrease in virus yield was more than linear compared to the decrease in inoculum. This may be explained by a high proportion of virus particles that do not successfully undergo a full infectious cycle, as noticed earlier (10) . Alternatively or in addition more than one virus particle might be required for the productive infection of a cell, leading to a more than proportional decrease in infectivity with lower virus concentrations. Quantitative RT-PCR of a genomic fragment comprising the Envelope protein coding region (11) with comparison to a standard (kind gift by M. L. Schmidt, Robert Koch Institute, Berlin, Germany) revealed that up to 1.6*10 6 copies of viral genomic RNA were released from each cell in the infected culture. This was confirmed (Suppl. Fig. 1 ) by using an additional primer set that binds to a different portion of the virus genome to amplify a fragment close to the 5" region of the positive genomic RNA (the RdRP/NSP12 coding region), which according to (24) is hardly involved in subgenomic fragments. Given the length of the viral genome of roughly 3*10 4 nucleotides, this suggests that one infected cell needs to produce at least 3*1.6*10 10 = 4.8*10 10 nucleotides for virus RNA synthesisand this does not include subgenomic virus RNA to encode virus proteins, nor negative strand RNA intermediates. Hence, virus production requires at least 8 times more nucleotides than the replication of the cellular genome (6*10 9 nucleotides in a diploid human cell). By this calculation, the demand of virus replication on nucleotide biosynthesis corresponds to more than what is needed for the re-synthesis of all ribosomal RNAs, assuming 5*10 6 ribosomes per cell (25, 26) and 7*10 3 ribonucleotides per ribosome. Considering these numbers, we reasoned that nucleotide biosynthesis might represent a limiting factor for virus replication, and hence a suitable drug target. As a strategy to interfere with nucleotide biosynthesis, and hence with virus replication, we treated Vero cells with MTX 24 hours before and during infection with SARS-CoV-2. Strikingly, the treatment with MTX strongly antagonized the infection. MTX largely prevented the cytopathic effect (CPE) observed in infected cells, whereas up to 10 µM MTX did not produce obvious morphologic signs of cytotoxicity ( Fig. 2A) , in agreement with recent reports (27, 28) . The amount of virus RNA released into the media was reduced up to 1000-fold by MTX in Vero cells (Fig. 2B) , and the effective concentration of MTX was around 1 µM, which was lower than the effective concentration of the established antiviral drug remdesivir, i.e. 10 µM (Fig. 2B ). MTX diminished SARS-CoV-2 progeny up to 100-fold in Calu-3 cells (Fig. 2C) , a cell line that can be used to model bronchial epithelia (29) . Moreover, similar results were obtained when the TCID50 (Median Tissue Culture Infectious Dose)/ml was determined as a readout for virus yield (Fig. 2D ). Most notably, MTX did not only reduce virus yield in Vero cells that were treated 24 hours before virus infection (Fig. 2E ), but also diminished virus progeny in cells that were only treated with MTX right at the time of SARS-CoV-2 infection (Fig. 2F ) and even when MTX was added 4 hours after infection (Suppl. Fig. 2 ). Taken together, these results indicate that MTX is a potent inhibitor of SARS-CoV-2 replication. To obtain a first idea about the stage of the infectious cycle affected by MTX, we detected viral proteins upon treating the cells with MTX and infecting them with SARS-CoV-2. The detection rate of viral nucleoprotein and thus the rate of SARS-CoV-2 positive cells was severely reduced by MTX as determined by immunofluorescence microscopy (Fig. 3A, B) . In accordance with this observation, immunoblot analysis of Vero cells revealed that infected cells contained high amounts of the viral N and S proteins, whereas the amounts of these proteins were strongly diminished by MTX (Fig. 3C ). This argues that not just the release of virus particles is diminished by MTX, but also the earlier steps of the infectious cycle, i.e. the synthesis of virus proteins. The antiviral effect of MTX is a result of defective purine synthesis but not phenocopied by CDK inhibition. MTX can slow down cell cycle progression (30) . Accordingly, cells treated with MTX proliferated more slowly compared to untreated control cells but did not increase the release of LDH, indicating that the cytotoxicity levels remain unchanged upon MTX treatment (Fig. 4A) . To determine whether a cell cycle arrest might be accountable for decreased virus replication upon MTX treatment, we performed flow cytometry and compared MTX with palbociclib, a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6 (31) . Compared to the control, MTX treatment increased the levels of the tumor suppressor p53 and its target gene product p21, as well as its target gene product dihydrofolate reductase (DHFR), as described (32) . Palbociclib increased the levels of its target CDK4, as reported previously (33) (Fig. 4B ). Although both drugs impaired cell proliferation (Fig. 4C) , palbociclib did not affect the synthesis of SARS-CoV-2 specific proteins (Fig. 4B ) nor virus replication (Fig. 4D) , indicating that the antiviral effect of MTX can not be explained solely by cell cycle arrest. MTX interferes with a number of metabolic steps (Fig. 5A) after cellular uptake and polyglutamation (5, 34, 35) . First and foremost, it inhibits dihydrofolate reductase (DHFR) (36, 37) . However, purine synthesis is inhibited by MTX even under conditions when the directly required folate metabolite, 10-formyl-THF, is largely preserved in its levels (38) . This argues that MTX diminishes purine synthesis, at least to a substantial extent, by direct inhibition of one of its metabolic steps. And indeed, polyglutamated MTX inhibits phosphoribosylaminoimidazolecarboxamide (AICAR) transformylase (ATIC) (39, 40) . MTX, when polyglutamated, also inhibits thymidylate synthetase (TYMS) directly (41, 42) , which, along with the depletion of 5,10 methylene THF, further diminishes the synthesis of deoxythymidine monophosphate (43) . This then reduces the availability of deoxythymidine triphosphate, which is required for the synthesis of DNA but not RNA. Finally, MTX also acts as an inhibitor of methylene tetrahydrofolate-reductase (MTHFR) (44) . In addition to the shortage of the MTHFR substrate 5,10 methylene THF, this direct inhibition reduces the regeneration of methionine from homocysteine. Methionine is required to synthesize S-adenosylmethionine (SAM), a necessary substrate of methylations of proteins (e.g. histones) as well as the RNA 5"-cap. To determine the impact of MTX on the metabolism of infected cells, we asked whether purine synthesis might be diminished by MTX treatment in the context of infection. One key product of purine synthesis is represented by ATP. To determine ATP levels in MTX-treated and/or virus-infected cells, we rapidly lysed the cells in a chaotropic buffer, followed by dilution and addition of luciferin and luciferase to cell lysates, and luminometry. In this assay system, the levels of ATP are directly reflected by the extent of luminescence. Simultaneously, we determined the corresponding cell numbers by DAPI-staining of cell nuclei and automated quantification. When calculating the relative amount of ATP per cell, we found that MTX reduced ATP levels about three-to fivefold in infected as well as non-infected cells, suggesting that MTX impairs purine synthesis even upon infection with SARS-CoV-2 (Fig. 5B ). Next, we performed rescue experiments to elucidate the mechanism(s) required to interfere with virus replication. First, we added folinic acid (leucovorin) to the cells along with the MTX treatment. Remarkably, this fully rescued virus replication. Folinic acid is readily converted to 5,10 methylene THF, thus re-supplying the source of methylation required by all MTX-inhibited reactions (45) . The rescue strongly suggests that the impact of MTX on virus replication is indeed due to its competition with endogenous folic acid and its metabolism (Fig. 5C) . Moreover, the addition of inosine restored virus replication in the presence of MTX (Fig. 5D ). Both leucovorin and inosine were also capable of re-establishing the synthesis of virus N and S proteins (Fig. 5E ). Inosine is rapidly converted to inosine monophosphate (45, 46) , which otherwise represents the end point of purine synthesis. This indicates that purine synthesis, rather than the supply of thymidine or SAM, is critical for virus replication. From this, the reduced supply of ribonucleotides appears as the dominating mechanism of action allowing MTX to act in an antiviral fashion. Remdesivir is currently one of the most advanced antiviral drugs against SARS-CoV- roughly 50-75%, the combination of both drugs led to a reduction by more than 98% ( Fig. 6A and Suppl. Fig. 3 ) without increasing cytotoxicity towards non-infected cells (Fig. 6B) . Similarly, virus proteins were still detectable when the cells had been treated with single drugs at these concentrations, but the drug combination virtually extinguished the corresponding immunofluorescence signals (Fig. 6C ). We conclude that MTX enhances the efficacy of remdesivir, leading to synergistic therapeutic efficacy. Our results indicate that MTX efficiently inhibits the propagation of SARS-CoV-2, at least in the cell culture systems under study here. The inhibitory effect of MTX primarily relies on reduced purine synthesis. Moreover, MTX was combined with remdesivir to yield synergistic virus inhibition. Pending further testing in animals, these results are compatible with the idea of repurposing MTX as a drug for treating and/or preventing COVID-19, combining its known anti-inflammatory with the heredescribed antiviral effect. However, MTX might be more effective in cells that allow SARS-CoV-2 to replicate in high levels, thus raising the need for lots of nucleotides. We anticipate that MTX might be less potent in cells where the virus only replicates in moderate copy numbers, e.g in primary cells of bronchial epithelia. While this paper was presented as a manuscript on biorxiv, independent work was published to indicate the ability of MTX to block SARS-CoV-2 replication as well (28). On top of reporting this, our results provide additional insights into the impact of MTX on virus protein synthesis, the rescue by folic acid and purine, as well as the cooperative effect of MTX with remdesivir. Very recently, the interplay of SARS-CoV-2-infection and the metabolism of C1 bodies was elucidated in detail (50) and this report also confirmed (and cited) the results provided in our study. Of note, some virus replication was observed in the presence of even high amounts of MTX (as determined by qRT-PCR as well as TCID50, cf. Fig. 2 ). We propose that this is due to the use of existing purine nucleotides that are derived from degrading nucleic acids and the salvage pathway. This allows for a pool of nucleotides independent of purine synthesis, this pool may then be used for replicating a limited amount of virus RNA. (53) . Recently, a DHODH inhibitor was also found active against SARS-CoV-2 (54, 55) and might be re-purposed for treating SARS-CoV-2 infections as well, e.g. through a recently completed phase I trial (NCT04425252). In addition to purine synthesis, MTX also limits the transfer of C1 bodies (methyl groups) through MTHFR to regenerate S-adenosylmethionine (SAM), a major substrate for methyltransferases in the cell (5) . Since SAM is required for the capping of the viral (as well as cellular) RNA (56), this might further limit the production of infectious RNA. Indeed, the characterization of cellular metabolomics in response to SARS-CoV-2 infection, and the observed reduction in spermidine, at least suggested that SAM levels were reduced in infected cells (57) . However, based on the fact that the purine nucleoside inosine was capable of rescuing virus replication (Fig. 5D ), we propose that the lack of purine synthesis represents the major mechanism of how MTX limits SARS-CoV-2 replication. Using MTX against other viruses has been considered previously. As early as in Fig. 2 , the viral N and S proteins as well as DHFR, p53, p21, CDK4 and GAPDH (loading control) were detected by immunoblot analysis. Note that the virus protein levels remained unchanged upon palbociclib treatment. (C) Induction of a cell cycle arrest upon MTX and palbociclib treatment. Vero cells were treated with 1 µM MTX or palbociclib and infected with SARS-CoV-2 as in Fig. 2 . Flow cytometry was performed to analyze cell cycle progression. Note that both drugs induced a cell cycle arrest and therefore impaired cell proliferation. (D) Reduction of virus RNA progeny by MTX but not palbociclib. Vero cells were treated with 1 µM MTX/palbociclib, infected as in Fig. 2 . and the virus RNA was detected by quantitative RT-PCR. MTX was found capable of reducing virus RNA yield by more than 1000-fold, whereas palbociclib did not diminish virus replication (mean with SD, n=3). Mechanism of Action of Methotrexate Against Zika Virus Flaviviruses are sensitive to inhibition of thymidine synthesis pathways Antibacterial Antifolates: From Development through Resistance to the Next Generation. Cold Spring Harbor perspectives in medicine 6 Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid Methotrexate and its mechanisms of action in inflammatory arthritis Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia Quantitation of flaviviruses by fluorescent focus assay An Optimized High-Throughput Immuno-Plaque Assay for SARS-CoV-2 The basic reproductive number and particle-to-plaque ratio: comparison of these two parameters of viral infectivity Detection of 2019 novel coronavirus (2019-nCoV) by realtime RT-PCR. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 25 A new coronavirus associated with human respiratory disease in China Fast gapped-read alignment with Bowtie 2 A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data deepTools2: a next generation web server for deep-sequencing data analysis Variant Review with the Integrative Genomics Viewer Integrative genomics viewer Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology Identification of a common deletion in the spike protein of SARS-CoV-2 SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication Genes V BioNumbers--the database of key numbers in molecular and cell biology Reversal of Infected Host Gene Expression Identifies Repurposed Drug Candidates for COVID-19 Methotrexate inhibits SARS-CoV-2 virus replication "in vitro Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery Methotrexate cytotoxicity as related to irreversible S phase arrest in mouse L1210 leukemia cells Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought Species-specific differences in translational regulation of dihydrofolate reductase The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes How does methotrexate work? Methotrexate an Old Drug with New Tricks On the mechanism of action of aminopterin Inhibition of dihydrofolic reductase by aminopterin and amethopterin The effect of methotrexate on intracellular folate pools in human MCF-7 breast cancer cells. Evidence for direct inhibition of purine synthesis Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5'-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates Studies relating to the mode of action of methotrexate. 3. Inhibition of thymidylate synthetase in tissue culture cells and in cell-free systems Mechanism of thymidylate synthase inhibition by methotrexate in human neoplastic cell lines and normal human myeloid progenitor cells Polyglutamation of methotrexate. Is methotrexate a prodrug? Methotrexate--how does it really work? Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers Remdesivir for the Treatment of Covid-19 -Final Report Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial SARS-CoV-2 hijacks folate and one-carbon metabolism for viral replication Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF) Antiviral activities of mycophenolic acid and IMD-0354 against SARS-CoV-2 Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer 2021. The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines Dihydroorotate dehydrogenase inhibitors in SARS-CoV-2 infection Structural Basis of RNA Cap Modification by SARS-CoV-2 Coronavirus Analysis of SARS-CoV-2-controlled autophagy reveals spermidine, MK-2206 Folic acid deficiency and the sparing of mice infected with the virus of lymphocytic choriomeningitis Patients with rheumatoid arthritis treated with methotrexate (MTX): concentrations of steady-state erythrocyte MTX correlate to plasma concentrations and clinical efficacy High dose methotrexate in adult patients with osteosarcoma: clinical and pharmacokinetic results Methotrexate and misoprostol vs misoprostol alone for early abortion. A randomized controlled trial Methotrexate pharmacokinetics and effects in women receiving methotrexate 50 mg and 60 mg per square meter for early abortion Part II. high-dose methotrexate with leucovorin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced 'PANIC' attack 2020. Part I. SARS-CoV-2 triggered 'PANIC' attack in severe COVID-19 Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells Methotrexate Is a JAK/STAT Pathway Inhibitor Baricitinib as potential treatment for 2019-nCoV acute respiratory disease JAK Inhibition as a New Treatment Strategy for Patients with COVID-19 Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis We thank Stefan Pöhlmann, German Primate Center Göttingen, for helpful advice, Vero cells were inoculated with virus as in Fig. 2 , with or without MTX treatment 24 Unchanged cytotoxicity levels upon the combination treatment compared to single treatments. Vero cells were treated with MTX and/or remdesivir at the indicated concentration for 72 hrs. The LDH release into the supernatant upon disruption of the plasma membrane was measured and quantified by bioluminescence (mean with SD, n=3; control = maximum LDH release). Stronger reduction of viral protein synthesis by a combination of MTX and remdesivir compared to single treatments, as determined 48 hrs p.i. by immunofluorescence analysis.